Tuberculosis is a chronic disease that
has spread over the world. Drug companies are concentrating their efforts on
creating medications that can reduce the length of treatment and help overcome
the hurdles of drug-susceptible and drug-resistant TB. There are two forms of
TB treatment: first-line treatment, second-line treatment, and drug-resistant
treatment.
Although advanced technologies and the
development of novel therapies are expected to reduce the time it takes to
treat tuberculosis, most cases can take up to 6 months to treat with currently
available drugs. Despite existing medicines and ongoing TB treatment drug
advances, patients' access to suitable TB medicines continues to be a
challenge, particularly in the areas of multidrug-resistant TB and paediatric
TB.
Tuberculosis Drugs Market – Restraints
The rising number of medicine recalls
is a key stumbling block to the market's expansion. Manufacturers of tuberculosis
drugs market face obstacles such as an increase in product recalls due
to packaging or manufacturing defects. In India, for example, Sandoz recalled a
batch of tuberculosis (TB) medications due to improper packaging. Furthermore,
the Philippines Food and Medicine Administration recalled Novartis' drug
Onecure in 2016 due to an insufficient amount of rifampicin in the drug.
Another element limiting the market's
growth is the high cost of medications. Second-line therapy medications are
more expensive than first-line treatment drugs, and they have more side effects
and high levels of toxicity.
Tuberculosis Drugs Market - Regional Insights
The global tuberculosis
drugs market is divided into five regions: North America, Latin
America, Europe, Asia Pacific, the Middle East, and Africa.
Because of the higher cost of TB drugs
in the region, North America is likely to have a dominating position in the
global tuberculosis pharmaceuticals market over the forecast period. For
example, due to a transfer of rights to Rodelis Therapeutics, the price of the
Cycloserine medication for treating multidrug-resistant tuberculosis soared
from US$15 per tablet to US$360 per tablet in 2015.
Because of the high prevalence of
tuberculosis in Europe, the market is likely to rise over the forecast period.
According to the TB Europe Coalition, over 323,000 new tuberculosis infections
and 32,000 deaths were reported in Europe in 2015.
Comments
Post a Comment